Review
Open access
Sep 2026
ALKBH5 inhibitors for cancer therapy: molecular docking, challenges and future prospects
N 6 -Methyladenosine (m 6 A), the most abundant internal modification of eukaryotic mRNA, is dynamically reversed by the Fe II /α-ketoglutarate-dependent dioxygenase ALKBH5, a key m 6 A “eraser” that regulates target mRNA fate through demethylation. ALKBH5 is aberrantly overexpressed in acute myeloid leukemia...
Chen Deng, Hai Xu, Jian Pu et al.
· Frontiers in Pharmacology · 0 citations